Page 136 - 《中国药房》2021年2期
P. 136
库中组合查询 2006 年 7 月-2020 年 8 月发表的相关文 续表1
献,并就白薇的化学成分与药理作用的研究进展进行归 化合物名称 来源 参考文献
纳总结,为该药材的进一步开发与利用提供参考。 Cynanoside P2、P4~P5、Q1~Q3、R1~R3、S、Sublanceoside E3、Che- 直立白薇 [5]
kiangensoside C
1 化学成分 Atratoglaucoside A、Cynanoside Ⅰ 蔓生白薇 [15]
化学成分是中药材发挥药效的物质基础,也是评价 白前苷元C-3-O-β-D-黄花夹竹桃吡喃糖苷 蔓生白薇 [7,15]
白前苷D 直立白薇、蔓生白薇 [6,15]
中药材质量的重要依据。目前,已从白薇中鉴定出 C21
Cynanoside A 直立白薇 [11]
甾体皂苷类、挥发油类、生物碱类等化学成分,其中 C21 Cynanosides(C~D) 直立白薇、蔓生白薇 [11,15]
[2]
甾体皂苷类为其主要化学成分 。 Cynanoside K~O、Sublanceoside Ⅰ1 直立白薇 [4]
1.1 C21甾体皂苷类 Sublanceoside E1、Cynascyroside C 直立白薇 [4,11]
直立白薇 [5,9]
Cynanoside P1、Cynanoside P3
甾体皂苷由甾体苷元和糖基结合而成。其中,C21甾
Glaucogenin C-3-O-β-D-cymaropyranosyl-(1→4)-α-L-diginopyranosyl- 直立白薇 [7]
体是一类含有 21 个碳原子的甾体衍生物,存在于萝藦 (1→4)-β-D-thevetopyranoside、Glaucogenin C-3-O-β-D-cymaropyra-
科、玄参科、夹竹桃科、毛茛科等科属植物中,具有抗炎、 nosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-D-cymaropyranoside、Glau-
cogenin C-3-O-α-L-cymaropyranosyl-(1→4)-β-D-digitoxopyranosyl-
抗肿瘤、抗生育等生物活性 。白薇中的C21甾体皂苷具 (1→4)-β-D-thevetopyranoside、Glaucogenin A-3-O-β-D-cymaropyra-
[3]
nosyl-(1→4)-α-L-diginopyranosyl-(1→4)-β-D-cymaropyranoside、
有以下结构特点:(1)甾体皂苷苷元均以孕甾烷或其异
Glaucogenin A-3-O-α-L-cymaropy-ranosyl-(1→4)-β-D-digitoxopyra-
构体为基本骨架,C、D环易发生变形,具有特殊的14,15 nosyl-(1→4)-β-D-cymaropyranoside、Glaucogenin A-3-O-α-D-oleandro-
pyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-oleandropyra-
裂环(A型)或13,14;14,15双裂环结构(B、C型)(图1); noside、Glaucogenin A-3-O-α-L-cymaropyranosyl-(1→4)-β-D-digitoxo-
(2)苷元 C-3 位置上通常有β-OH,C-5、C-6 位通常有双 pyranosyl-(1→4)-β-D-digitoxopyranoside、Glaucogenin A-3-O-β-D-
oleandropyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-olean-
键;(3)糖链通常与苷元 C-3 位的 OH 相连,糖与糖之间 dropyranoside、Glaucogenin A-3-O-α-L-cymaropyranosyl-(1→4)-β-D-
的连接通常发生在C-4位;(4)糖的类型主要有黄花夹竹 cymaropyranosyl-(1→4)-β-D-oleandropyranoside、Glaucogenin A-3-O-
α-L-cymaropyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-β-D-cy-
桃糖、夹竹桃糖、洋地黄毒糖、地芰糖、加拿大麻糖和葡
maropyranoside、Glaucogenin A 3-O-β-D-glucopyranosyl-(1→4)-β-D-
萄糖,且通常为6-去氧糖或2,6-去氧糖 。 glucopyranosyl-(1→4)-β-D-oleandropyranoside、Glaucogenin A-3-O-
[2]
β-D-glucopyranosyl-(1→4)-α-L-cymaropyranosyl-(1→4)-β-D-digito-
xopyranosyl-(1→4)-β-D-cymaropyranoside、Neocynapanogenin F-3-O-
β-D-thevetopyranoside、Glaucogenin A-3-O-α-L-oleandropyranosyl-
(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-oleandropyranoside、
Glaucogenin C-3-O-α-D-oleandropyranosyl-(1→4)-β-D-digitoxopyra-
nosyl-(1→4)-β-D-oleandropyranoside
Glaucogenin C-3-O-α-L-diginopyranosyl-(1→4)-β-D-thevetopyrano- 直立白薇 [7,13]
side
A.14,15裂环(A型) B.13,14;14,15双裂环(B型)
3β,5α,6β-Trihydroxyl-15,20 ∶ 18,20-diepoxy-13,14:14,15-di- 直立白薇 [8]
secopregna-13(18)-eno-14-oicacid-16β-lactone、2α,3β,13α,18α-
Tetrahydroxyl-15,20 ∶ 18,20-diepoxy-13,14 ∶ 14,15-disecopregna-
5-eno-14-oicacid-16 β-lactone3-O-α-D-oleandropyranosyl-(1→4)-β-
D-digitoxo-pyranosyl-(1→4)-β-D-oleandropyranoside、Glaucogenin
C-3-O-β-D-glucopyranosyl-(1→4)-α-D-oleandropyranosyl-(1→4)-
β-D-digitoxopyranosyl-(1→4)-β-D-oleandropyranoside、3 β ,14 β-
Dihydroxy-pregn-5-en-20-one-3-O-β-D-(6-sinapoyl)-glucopy-ranosyl-
C.13,14;14,15双裂环(C型)
(1→2)-β-D-glucopyranoside
图1 白薇C21甾体皂苷苷元的基本骨架 (20S)-cynangenin C-3-O-β-D-cymaropyranoside、7-Desoxyneocynapa- 直立白薇 [9]
迄今为止,研究者已从白薇中鉴定出大量的 C21甾 nogenin A-3-O-β-D-thevetopyranoside、Cynangenin A-3-O-β-D-theve-
topyranoside、Cynanversicoside A、Atratoglaucoside A
体皂苷,具体如表1所示。从来源上看,从直立白薇中发
Cynaascyriogenin3-O-β-D-glucopyranosyl-(1→6)-β-D- glucopyranosyl- 直立白薇 [10]
现的C21甾体皂苷数量远远多于蔓生白薇 [4-17] ,二者共有 (1→4)-α-L-cymaro-pyranosyl-(1→4)-β-D-digitoxo-pyranosyl-(1→
的成分为蔓生白薇苷 A、C,白前苷 C、D、H,Atratoglau- 4)-β-D-cymaropyranoside
Sublanceoside L2、Sublanceoside H2、Mooreanoside H 直立白薇 [12]
coside A,Cynanosides C、D 和白前苷元 C-3-O-β-D-黄花
Glaucogenin C-3-O-β-D-oleandropyranosyl-(1→4)-β-D-digitoxo- 直立白薇 [13]
夹竹桃吡喃糖苷。 pyranosyl-(1→4)-α-L-cymaropyranoside、Glaucogenin C-3-O-β-D-
glucopyranosyl-(1→4)-β-D-glucopyranosyl-(1→4)-β-D-oleandropyr-
表1 从白薇中分离鉴定出来的C21甾体皂苷 anoside、Glaucogenin A-3-O-α-L-cymaropyranosyl-(1→4)-β-D-digi-
化合物名称 来源 参考文献 toxopyranosyl-(1→4)-β-D-oleandropyranoside、Glaucogenin A-3-O-α-
L-diginopyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-β-D-olean
直立白薇苷A、C,白前苷 A 直立白薇 [6,12] dr-opyranoside、Glaucogenin A-3-O-α-L-Cymaropyranosyl-(1→4)-
直 立 白 薇 苷 B、Amplexicogenin C-3-O-β-D-cymaropyranoside、 直立白薇 [6] α-L-cymaropyranosyl-(1→4)-β-D-oleandropyranoside、Glaucogenin
Hirundigoside C、Amplexicoside B A-3-O-α-L-cymaropyranosyl-(1→4)-β-L-cymaropyranosyl-(1→4)-β-L-
直立白薇苷D 直立白薇 [17] cymaropyranoside、Glaucogenin A-3-O-α-L-cymaropyranosyl-(1→4)-
直立白薇苷E 直立白薇 [12,17] β-D-cymaropyranosyl-(1→4)-β-L-cymaropyranoside
白前苷 C 蔓生白薇、直立白薇 [15,17] 蔓生白薇苷A、C 蔓生白薇、直立白薇 [15,17]
白前苷 H 蔓生白薇、直立白薇 [12,15,17] 蔓生白薇苷B、D、E 蔓生白薇 [15]
白薇苷A、C 直立白薇 [4,11] Cynanversicoside F 蔓生白薇 [14]
·254 · China Pharmacy 2021 Vol. 32 No. 2 中国药房 2021年第32卷第2期